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Abstract
Background: Seroreactivity, processes of seroconversion and seroreversion, in the context of HPV infection has
been investigated in numerous studies. However, the data resulting from these studies are usually not accounted
for in mathematical transmission models of various HPV types due to gaps in our understanding of the nature of
seroreactivity and its implications for HPV natural history.
Methods: In this study we selected a number of simple but plausible compartmental transmission models of HPV-16,
differing in assumptions regarding the relation between seropositivity and immunity, and attempted to calibrate them
to Australian HPV seroprevalence data for females and males, as well as DNA prevalence data for females, using a
Bayesian model comparison procedure. We ranked the models according to both their simplicity and ability to be
fitted to the data.
Results: Our results demonstrate that models with seroreversion where seropositivity indicates only a partial or very
short-term full protection against re-infection generate age-specific HPV DNA prevalence most consistent with the
observed data when compared with other models.
Conclusions: Models supporting the notion that seropositive individuals are fully immune to reinfection demonstrated
consistently inferior fits to the data than other models making no such assumption.
Keywords: Seroreactivity, Compartmental model, HPV, Natural immunity
Background
Genital human papillomaviruses (HPV) are viral sexually
transmitted infections (STIs) with around 40 types having
tropism for the anogenital region. High-risk (oncogenic)
HPV types 16 and 18 are more virulent than others and
associated with about 70-76% of cervical cancers [1,2]. Of
these two, type 16 is more prevalent [3,4] and responsible
for the highest proportion of cervical cancers (> 50%) [1,5].
To prevent the spread of cervical cancer and other HPV
associated diseases such as genital warts caused by the
low-risk (nononcogenic) HPV types 6 and 11, many de-
veloped countries are now implementing comprehensive
vaccination programs [6-8] utilising highly effective
prophylactic HPV vaccines CervarixW (bivalent vaccine;
protects against HPV types 16 and 18) or GardasilW
(quadrivalent vaccine; protects against HPV types 6, 11, 16
and 18).
Because cancer generally develops long after initial infec-
tion with HPV, the actual impact of vaccination programs
for cancer prevention will not be known for decades after
these programs have commenced. Mathematical models
have therefore been commonly employed to predict the
potential population-level impact of vaccination under dif-
ferent vaccination scenarios and assumptions regarding
vaccine properties.
Mathematical transmission models can be constructed
in a number of ways but deterministic compartmental
models are commonly used due to their relative simpli-
city and tractability [9-14]. A typical compartmental
model is described by a nonlinear system of ordinary
differential equations (ODEs) governing changes in the* Correspondence: ikorostil@kirby.unsw.edu.au1The Kirby Institute, University of New South Wales, Sydney, NSW 2052,
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number (or proportions) of individuals in pre-specified
subgroups of the modelled population over time.
A necessary element of every modelling study is model
calibration. Calibration is performed by adjustment of par-
ameter values to ensure that the model predictions, which
are intrinsically uncertain, are consistent with available
real-life data. The accuracy of the calibration process can
be iteratively improved as more data become available.
Often HPV models are calibrated to HPV incidence or
prevalence data collected in a particular country or juris-
diction. In view of increasing availability of data related
to seroreactivity (production of antibodies in response to
infection, known as seroconversion, and their decay, or
seroreversion), it is timely to investigate the present possi-
bilities to use them for model calibration. A number of
studies (for example, [15-18]) report seroprevalence by
age or other characteristics, estimated times from HPV
DNA detection to detection of seropositivity, and rates of
seroconversion or seroreversion. With the exception of a
single modelling study we are aware of [9], these data have
not been considered in the development and calibration of
transmission because the relationship between seroposi-
tivity and immunity is not well understood. However, we
believe that it is worthwhile to investigate a few possible
associations that may exist between seroreactivity and
HPV transmission. The key association that we focus on
in this study is that between seropositivity and natural im-
munity developed after resolution of an HPV infection.
In this study, we develop eight compartmental models
based on types SIS (Susceptible-Infected-Susceptible), SIR
(Susceptible-Infected-Recovered) and SIRS (Susceptible-
Infected-Recovered-Susceptible) [19,20], which incorpor-
ate different assumptions regarding the relation between
seropositivity and immunity. Our models aim to obey the
principle of parsimony, which loosely states that among
competing hypotheses the simplest one should be
selected. In practice, this means that if the literature pre-
sents several conflicting views on an aspect of HPV trans-
mission, we prefer to adopt the one which is described by
fewer parameters. By minimizing the number of para-
meters we increase their explanatory power. We rank the
models in terms of their simplicity combined with ability




Since we intended to calibrate our models to Australian
data, it was important to ensure that the population we
modelled was a reasonably accurate representation of
the sexually active heterosexual Australian population.
We defined the modelled population as a set of non-
overlapping groups of individuals stratified by gender,
age, sexual activity and infection state. In compartmental
models (sometimes referred to as population-based
models, in contrast with individual-based models), each
of these groups (“compartments”) is assumed to be large
enough to behave independently of individual stochastic
effects. Throughout this paper, when we refer to an “in-
dividual” from a particular compartment, we actually
mean a descriptor representing the whole population in
that compartment, whose attributes are averaged attri-
butes of that population. The age structure of the popu-
lation was represented by 48 one-year age groups in the
range 12 to 59 years of age. This was motivated by the
following factors: 1) to model HPV we need to model only
the sexually active Australian population, which excludes
those younger than a certain age: in our models indi-
viduals start sexual activity at 15, but we also included
12–14 year olds, to allow for possible extension of the
model should sexual behaviour data for this age group be-
come available; 2) the sexual behaviour data we used [21]
do not cover individuals older than 60, and no alternative
data were available.
Sexual activity was described by four groups defined by
the annual number of new sexual partners. These groups
are numbered 1 to 4 in order of increasing activity and
contain 60%, 27%, 11% and 2% of the modelled popula-
tion, respectively [22]. Infection states were as follows:
susceptible (S; an individual is susceptible if he or she is at
risk of infection); infected (I; an individual who is cur-
rently infected; infected individuals are assumed to be
both infectious and DNA positive); and recovered (R; an
individual in this infection state has resolved his or her in-
fection, tests HPV DNA negative, and is fully immune to
re-infection). For compartmental models, the total size of
the population is not important for analysis, but was set
arbitrarily to 100,000. The population was assumed to be
closed, i.e. immigrants, emigrants and temporary visitors
were not considered (whether this plays an important role
for HPV transmission in Australia has not been estab-
lished but determining this is outside the scope of the
present study). Mortality was also not considered for the
following reasons: 1) we did not model progression to
cancer and there is no mortality directly associated with
HPV infection; 2) the age-specific mortality profile for the
age range of the modelled population is fairly flat such
that deaths from other causes can be ignored [23]. While
births are not modelled explicitly, the modelled popula-
tion is replenished with 12 year-olds at an annual rate
equal to that at which exit from the sexually active popu-
lation occurs at age 60.
Sexual mixing
Sexual behaviour in the Australian population is described
in our models by means of a mixing matrix which quanti-
fies the rate of new partner acquisition by males and
females based on their age and level of sexual activity. Our
Korostil et al. BMC Infectious Diseases 2013, 13:83 Page 2 of 9
http://www.biomedcentral.com/1471-2334/13/83
implementation of the mixing matrix is as previously
employed and described in [9,11], and is based on a for-
mulation developed by Garnett and Anderson [24]. The
parameters of the matrix are specified as in [22] based on
an analysis of data from the Australian Study of Health
and Relationships (ASHR) [21].
Natural history of HPV-16
Differences between the models we evaluate here are in
terms of what is assumed in regard to naturally acquired
immunity, i.e. immunity acquired as a result of exposure to
infection. In this study we evaluate two general scenarios:
either individuals cannot become reinfected while being
seropositive, or they can. The implementations of seroreac-
tivity, by model, are briefly summarized in Table 1.
The models we refer to as SIS (see Figure 1) are not
classical SIS models where individuals become fully sus-
ceptible to reinfection following clearance. In our SIS
models, individuals enter a model in the S state (suscep-
tibles) being seronegative (hence the state is marked
as S-). Then they can acquire a sexual partner who is
infected and move to state I (infected) themselves. This
is followed by clearance of infection, which can result
either in a move back to the state S- (no seroconversion
occurred), or to state S+. Individuals in S+ are seroposi-
tive and susceptible to reinfection with HPV-16. How-
ever, we let them have a degree of immunity varying
from none to full (parameter s changing from 0 to 1).
This degree is to be inferred by the calibration process.
Note that in the limit cases, the models turn into a clas-
sical SIR (if s=1), where R is a fully immune state where
individuals stay for life, or SIS (if s=0). It is also worth
mentioning that the partly immune individuals in S+ are
more likely to become infected again if they are more
sexually active. This is in contrast to classical interpreta-
tions of the immune state usually imposing fixed dura-
tions of immunity depending on individuals’ age, but not
sexual activity. Model SIS1 does not incorporate serore-
version (the decay or loss of antibodies detectable by
current assays in an individual): seropositive individuals
remain seropositive for life. On the other hand, in SIS2
they are assumed to be losing antibodies at a constant
rate while in the state S+, so there is a steady migration
of individuals from S+ to S- as they lose whatever degree
of immunity they had.
In our SIS models females who cleared infection are
ensured a degree of natural immunity (see prior distri-
butions in Table 2), while males may or may not be
protected.
The key feature of SIR models (Figure 2) is that
infected individuals eventually develop life-long immun-
ity to reinfection. In both models they can clear infection
with or without seroconversion. If they do seroconvert,
this happens simultaneously with clearance, and sero-
positive individuals are necessarily in the R state (SIR1).
In SIR2, individuals can test seropositive and still remain
infected for some time.
In SIRS models (Figure 3), where immunity is allowed
to wane, individuals return from the R state to the S state.
Model SIRS1 is essentially SIR1 with waning immunity.
Note that we assume no difference in the rates of loss of
immunity between seropositive (R+) and seronegative
(R-) immune individuals, and losing immunity is equiva-
lent to losing seropositive status. Similarly, SIRS2 is an
extension of SIR2. Model SIRS3, just like SIR1 or SIRS1,
assumes that clearance and seroconversion are syn-
chronous, but seropositivity is not an indication of
immunity. Consequently, seropositive individuals lose
immunity at the same rate as seronegative ones and then
can become infected while testing seropositive. Seroposi-
tive status is life-long.
Finally, SIRS4 is SIRS3 with seroreversion. Both sus-
ceptible and immune individuals who seroconverted due
to previous infection are losing antibodies at a constant
rate which is different for males and females.
Note that in order to limit complexity, we chose not
to model the scenario whereby an individual can serore-
vert while infected, since in the infected state the level of
antibodies can be assumed to be high - there is, however,
no evidence to convincingly support this hypothesis.
Table 1 Implementation of seroreactivity in the compared models, their DIC scores and ranking








Reduced risk of re-infection
while seropositive
Risk of re-infection while
seropositive is unchanged
SIS1 – ✓ – – – −101.3 3
SIS2 – ✓ – – ✓ −108.8 1
SIR1 ✓ – – – – −28.6 8
SIR2 ✓ – – ✓ – −31.2 7
SIRS1 ✓ – – – ✓ −40.4 6
SIRS2 ✓ – – ✓ ✓ −45.7 5
SIRS3 – – ✓ – – −93.4 4
SIRS4 – – ✓ – ✓ −105.6 2
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Model parameters are gender specific, which allows for
possible differences in HPV-16 natural history between
females and males. The ordinary differential equations de-
scribing the models included in this comparison are pro-
vided in the Additional file 1: Technical Appendix.
Model comparison and calibration
According to the Bayesian approach we adopted, it is ne-
cessary to formulate our beliefs about each of the model
parameters, before any data produced by the models
have been observed, as probability distributions. These
distributions are known as prior distributions or “priors”.
The priors we used in this study are given in Table 2
and discussed in the Additional file 1: Technical Appendix.
We applied a forward simulation procedure with adaptive
Markov chain Monte Carlo (as described in [38]) to cali-
brate each of the models under consideration to Australian
HPV-16 seroprevalence data for males and females [17]
and DNA prevalence data for females aged 15–39 [39].
During the calibration procedure, quantities required to
apply the deviance information criterion (DIC) [40] were
calculated. We chose DIC as a means to quantify the
parsimony of the models and the goodness of fit of the
outcomes they produced to real data after careful consid-
eration of a number of other statistics, such as Bayes fac-
tor and Akaike information criterion (see [41,42] or [43]
Figure 1 SIS models: SIS1 (left) and SIS2 (right); “+” and “-” denote seropositivity and seronegativity, respectively.
Table 2 Model parameters and their prior distributions
Parameter description Symbol Prior Source
Per-partnership probability of transmission from female to male used to
calculate the force of infection λ.
βm U(0.10-1.00) [25]
Per-partnership probability of transmission from male to female used to
calculate the force of infection λ.
βf U(0.10-1.00) [25]
Average duration of infection for males Tin,m U(0.60,1.70) [26,27]
Average duration of infection for females Tin,f U(0.75,1.50) [28-30]
Average rate of loss of immunity for males; defined as 1/Tim,m i.e. the inverse of
the average duration of natural immunity for males
rli,m U(0.01,0.33) (SIRS1, SIRS2); U
(0.01,1.0) (SIRS3, SIRS4);
[31] (SIRS1, SIRS2); Not
available (SIRS3, SIRS4);
Average rate of loss of immunity for females; defined as 1/Tim,f i.e. the inverse
of the of natural immunity for females
rli,f U(0.01,0.33) (SIRS1, SIRS2); U
(0.01,1.0) (SIRS3, SIRS4);
[31] (SIRS1, SIRS2); Not
available (SIRS3, SIRS4);
Probability of seroconversion for males pm U(0.01,0.30) [15]
Probability of seroconversion for females pf U(0.40,0.70) [32]
Average rate of seroreversion for males rsr,m U(0.01,0.10) [33]
Average rate of seroreversion for females rsr,f U(0.10,1.00) [18,32,34]
Average degree of immunity for seropositive males sm U(0.00,1.00) Not available
Average degree of immunity for seropositive females sf U(0.10,1.00) [35-37]
Average time to seroconversion for males (a proportion of Tin,m) Tsc,m U(0.50,0.95) [15]
Average time to conversion for females (a proportion of Tin,f) Tsc,f U(0.50,0.95) [32,33]
Degree of assortativity by age group εa U(0.10,0.90) Not available
Degree of assortativity by sexual activity group εr U(0.10,0.90) Not available
All durations are in years, and all rates are per capita annual rates.
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for an extensive overview of approaches to model se-
lection) because it is simple to implement given the
samples generated by a Markov chain Monte Carlo
simulation. It is pertinent to note that fitting was done
to all data at once and the results we obtained would
not necessarily coincide with the results produced via
fitting to only some of the data (for example, only HPV
DNA prevalence). Another important detail is that we
did not fix the two sexual mixing parameters εa and εr
describing assortativity by age and sexual activity group
(see the Additional file 1: Technical Appendix), instead
treating them as ordinary parameters with the assigned
uniform prior distributions U(0.1,0.9). This was moti-
vated by the fact that these parameters are very difficult
to derive for a particular population based on data from
currently available sexual behaviour surveys. Conse-
quently, sexual behaviour was not enforced to be iden-
tical in all models.
Figure 2 SIR models: SIR1 (left) and SIR2 (right); “+” and “-” denote seropositivity and seronegativity, respectively.
Figure 3 SIRS models: SIRS1 (top left), SIRS2 (top right), SIRS3 (bottom left) and SIRS4 (bottom right); “+” and “-” denote seropositivity
and seronegativity, respectively.
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Results
The DIC values, calculated for each tested model, are
presented in Table 1. There is no rigorous specification
of what magnitude of difference in DIC scores indicates
a strong preference in favour of a model with the lower
score, but some authors recommend using a difference
of 10, as a rule of thumb [44]. By this rule of thumb, all
models in which seropositivity is associated with full im-
munity (SIR1, SIRS1, SIR2, SIRS2) are clearly inferior to
the other models. Allowing seroconversion prior to
clearance of infection in SIR1, and SIRS1 (which turn
them into SIR2 and SIRS2, respectively) somewhat
improves their scores, but these are still not competitive.
Calibration plots for all models can be found in the
Additional file 1: Technical Appendix, along with com-
prehensive descriptions of the posterior distributions for
model parameters.
Here we would like to briefly comment on some of the
inferred parameter values for the two “best” models SIS2
and SIRS4. Firstly, we observe that in SIS2 the per-
partnership transmission probability from male to fe-
male (βf, posterior median 0.806 and the 95% Highest
Posterior Density (HPD) interval, i.e. the shortest inter-
val in parameter space which contains 95% of the distri-
bution, (0.514-0.999)) is higher than that from female to
male (βm , posterior median 0.59, 95% HPD interval
0.248-0.961)). This is also the case for SIRS4, where the
posterior mean for βf is 0.885 against 0.695 for βm.
These values are consistent with the values predicted in
other modelling studies: for example, β (assumed to be
the same for female to male and male to female) was
estimated at 0.8 (median) with the 95% posterior interval
(0.6, 0.99) in [6], at 0.6 in [9] and 0.4 in [7]. There was,
however, a study which reported higher rates of female-
to-male relative to male-to-female transmission [45].
Posteriors for the average durations of HPV-16 infection
are left-skewed for both genders, with median at 1.367
(years) for males and 1.30 for females in SIS2 and 1.48
(males) and 1.367 (females) in SIRS4. In SIS2 the probability
of seroconversion for males pm is low (median at 0.135),
and for females (pf) it is not higher than the values
reported in literature. In particular, its posterior median is
at 0.494 while the 95% HPD interval is (0.4-0.654), which is
in agreement with 0.5-0.6 suggested in [32]. Somewhat
higher pm and pf were observed for SIRS4. The inferred
values for the degree of immunity for males do not let
us make any meaningful conclusions regarding whether
or not males are protected, because sm appears to have
little influence on the model performance, which is evi-
dent from its nearly flat posterior and 95% HPD inter-
val (0.001-0.903). In contrast, the degree of protection
for females, sf, has a non-flat posterior, and its 95%
HPD interval (0.100-0.810) suggests that we can at least be
reasonably confident that it is certainly not complete and
does not exceed 0.81, which is an important implica-
tion. Another modelling study [14], where degrees of
natural immunity were introduced in a manner similar
to ours, estimated them at 0.5 for both genders. Rates
of loss of immunity (SIRS4) were high for both males
and females, 95% HPD interval for males is (0.365-
0.999) and for females (0.403-1.0). These indicate very
short average durations of natural immunity, namely,
1–2.74 years for males and 1–2.48 years for females.
Finally, the rates of seroreversion under SIS2 are low
but higher for females than for males (median 0.08
against 0.03). Under SIRS4 these are very similar
(median 0.079 for females and 0.03 for males).
Discussion
The results we obtained show that models assuming that
seropositive individuals are fully and permanently pro-
tected from reinfection with HPV-16 are clearly inferior
to the other models making no such strong assumptions.
This conclusion is based on DIC scores. It is important
to realise that DIC does not detect a ‘correct’ model in
terms of HPV-16 transmission mechanism. Instead, it
provides a quantitative model ranking which discourages
complexity and is based on the ability of models under
consideration (among which the ‘correct’ model may not
even be present) to be fitted to the data. Hence, if a sim-
pler model can be calibrated to the data at least as well
as a more complex model, it will get a better DIC score.
To receive a better DIC ranking, a more complex model
would have to justify its complexity by producing a not-
ably better fit than its simpler competitors. To further
clarify the context in which our results should be viewed,
we mention that our results can be meaningfully inter-
preted only if we completely rely on the available data –
should these be extended or replaced, our results would
inevitably change too. Another important aspect is that
the DIC ranking factors in how well the models can be
fitted to all data at once, for both males and females. If we,
for instance, restricted ourselves to only calibrating the
models to HPV seroprevalence, the resulting model rank-
ing would likely be different.
As is evident from Table 1, our ‘best’ model is SIS2,
closely followed by SIRS4. The difference in DIC scores
between the two models is not substantial and hence does
not imply that SIS2 is clearly preferable. We should note
that the reason why SIS2 outscored SIS1 is inclusion of
seroreversion. Indeed, it is the only difference between the
models. Seroreversion in SIS2 is implemented with the
help of two additional parameters (rsr,m and rsr,f), as
compared with SIS1, and nonetheless, it improved the fit
substantially enough to overcome penalisation for extra
parameters and get ahead of SIS1 by 8.5 points. The bene-
fits of seroreversion in SIS1 are predictable since without
it, SIS1 can not capture declining seroprevalence in older
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females. For the same reason, SIRS4 provided a significant
improvement over SIRS3. We see that seroreversion in SIS
and SIRS models is crucial in terms of improving the fit to
data, even though the rate of seroreversion is low.
Although the highest ranking models SIS2 and SIRS4
have different structures, as we mentioned in Results, the
fitted durations of full natural immunity in SIRS4 are very
short. Hence, this model is approaching a limit case when
it almost becomes SIS2 (see Figure 1 and Figure 3).
It is our view, given what is currently known about
immunity (in particular, the reported association between
seropositivity and reductions in the number of incident
infections in seropositive individuals [34,35]), that the
protection mechanism assumed in SIS2 may be a more
realistic representation of naturally acquired protective
immunity than a short but full immunity as in SIRS4.
It is important to note that nearly all information avail-
able regarding the possible association of seropositivity with
protective immunity has come from studies of females. The
only study of males in this context that we are aware of
[16] suggests that for males seropositivity is possible with-
out any immunity. No substantiated inferences in regard to
the existence of protective immunity in males resulted from
our study: SIS2 was not sensitive to variations in the degree
of immunity in males. To increase sensitivity, the amount
of data used for model specification and calibration and/
or their accuracy should be increased, which we expect to
happen in future, when, for example, HPV DNA seropreva-
lence data for males become available.
Our models have a number of limitations. In particular,
we assumed the duration of immunity to be the same for
all ages, which is unlikely to be true in reality, and the
probability of seroconversion to be independent of an indi-
vidual’s age though there is some evidence to the contrary
[34]. Additionally, compartmental models are inherently
biased in certain respects. Because they assume a sexual
contact is effectively instantaneous, to achieve better fit to
real data, compartmental models need to compensate for a
somewhat lowered level of sexual activity by maintaining
higher probabilities of transmission and longer durations
of infection (see [46] for detailed discussion). It is also
important to remember that considerable uncertainty
remains in our understanding of HPV natural history
which influence our specification of priors for model para-
meters. Also, reliability of data obtained from sexual behav-
ior surveys may be arguable. Finally, the results of this
study rely on the data we calibrated our models to, which
had their own limitations (see [17,39] for discussion). Per-
haps, the most evident limitation is that HPV-16 preva-
lence data only covered women aged 15–39.
Conclusions
In conclusion, the models which provided the optimal
combination of parsimony and goodness of fit to the
currently available Australian data are these where sero-
positivity indicates only a partial (or very short full)
immunity against re-infection and seroreversion is
assumed to be taking place. Future studies will no doubt
provide greater insight into the nature of acquired im-
munity and its association with seropositivity, enabling
us to build more accurate models.
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